alexa Chronic Myeloid Leukemia - STOP TKI - Case Report In A 9-year-old Boy | 100360
ISSN: 2161-0665

Pediatrics & Therapeutics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Chronic myeloid leukemia - STOP TKI - Case report in a 9-year-old boy

World Congress on Clinical Pediatrics and Pediatric Oncology & Care

Carolina Maria Costa Pavao, Silvia Silva,Catia Sousa, Filipa Leite,Catarina Sousa,Marta Almeida, Ana Maia Ferreira,Vitor Costa, Tereza Oliva andArmando Pinto

Hospital do Divino Espirito Santo,PortugalInstituto Portugues deOncologia do Porto,Portugal

Posters & Accepted Abstracts: Pediatr Ther

DOI: 10.4172/2161-0665-C10-079

Abstract
Chronic myelogenous leukemia (CML) is relatively rare in children. Treatment is not standardized and often follows guidelines for adults. Because children with CML may receive tyrosine kinase inhibitor (TKI) therapy for many decades, and are exposed to TKIs during a period of active growth, morbidity can be more frequent. We report a case of a 9-year-old boy that presented with pallor and B symptoms. He was observed by his family???s doctor that noticed a hepatosplenomegally on abdominal palpation, that was confirmed by ultrasound. An analytical study was performed and detected an anemia of 8.2 g/dl and hyperleukocytosis of 33500 / uL. Immunophenotyping of bone marrow demonstrated 7,27% of blasts myeloids. Bone marrow biopsy presented invasion by myeloproliferative neoplasia. Cytogenetic analysis showed translocation (9;22) in 20 metaphases and molecular genetics demonstrated a rearrangement corresponding to the BCR-ABL fusion gene with a relative expression of 43,38% by quantitative RTPCR. These changes were compatible with the diagnosis of CML. He was started with imatinib 400mg/m2 in October 2011. An optimal response to therapy was observed, however, always with poor tolerance and weight loss, which led to the suspension of imatinib in April 2015. Then he was started on Dasatinib 64 mg/ m2 and presented an optimal response and tolerance during two years. Because he presented a major sustained molecular response during this period it was decided to discontinue dasatinib in May 2017. Currently he is followed monthly, with quantitative RT-PCR performing that shows sustained major molecular response.
Biography

Carolina Maria Costa Pavão has completed her MD with master degree in 2014 from the Faculty of Medicine of the University of Coimbra. Started her residency in clinical hematology in the hematology service of the Hospital do Divino Espírito Santo, Ponta Delgada, Portugal, in January of 2016, being currently attending the third year of her specific five year formation. As part of this programme she completed an intership in oncology pediatrics at Porto Oncology Institute in 2018.

E-mail: [email protected]

 

Leave Your Message 24x7
Top